SCHEMBL3211853

SCHEMBL3211853

CC1=[C]N(C)CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2650740 0.51
SCHEMBL5834880 0.50
SCHEMBL6902250 0.47
SCHEMBL1351735 0.47
SCHEMBL5634359 0.47
SCHEMBL2625118 0.45
SCHEMBL7946945 0.43
SCHEMBL5533138 0.43
SCHEMBL245729 0.43
SCHEMBL18285616 0.41

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4295852-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2023-12-27 EP claimed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP claimed
US-20230062491-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2023-03-02 US claimed
US-20230000870-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-01-05 US claimed
CN-114901284-A Methods of treating cancer in patients identified by biomarkers with cyclin dependent kinase 7(CDK7) inhibitors 希洛斯医药品股份有限公司 2022-08-12 CN claimed
WO-2021087138-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2021-05-06 WO claimed
EP-3484871-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2019-05-22 EP claimed
WO-2018013867-A1 INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) MARINEAU JASON J (US) 2018-01-18 WO claimed
EP-2091542-A1 NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE F. Hoffmann-Roche AG (CH) 2009-08-26 EP claimed
US-20090082402-A1 Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase ROCHE PALO ALTO LLC 2009-03-26 US claimed
WO-2008074678-A1 NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO claimed
CN-1170813-C N2 phenylamidine derivatives �ݶ�ũ�����޹�˾ 2004-10-13 CN claimed
EP-4295852-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2023-12-27 EP disclosed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
US-20230062491-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2023-03-02 US disclosed
US-20230000870-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-01-05 US disclosed
US-5484934-A FUNGICIDE, WOOD PRESERVATIVE NIHON NOHYAKU CO., LTD. (JP) 1996-01-16 US disclosed
EP-0604978-A1 Isothiazole derivatives, a process for production thereof and uses thereof NIHON NOHYAKU CO., LTD. (JP) 1994-07-06 EP disclosed
US-5202321-A Antihistamine, antiallergens, antiinflammatory agents MERCK FROSST CANADA, INC. (CA) 1993-04-13 US disclosed
EP-0518426-A1 Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA INC. (CA) 1992-12-16 EP disclosed